| Human immunodeficiency virus I infection
Genvoya vs Isentress
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Genvoya vs Isentress with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsIsentress has a higher rate of injection site reactions vs Genvoya based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Isentress but not Genvoya, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Genvoya
Isentress
At A Glance
Oral
Once daily
Fixed-dose combination: INSTI + CYP3A inhibitor + NRTIs
Oral
Once or twice daily
HIV-1 integrase strand transfer inhibitor
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection One tablet (150 mg EVG, 150 mg COBI, 200 mg FTC, 10 mg TAF) orally once daily with food in patients weighing at least 25 kg with creatinine clearance >=30 mL/min, or adults with creatinine clearance <15 mL/min receiving chronic hemodialysis (administer after hemodialysis on dialysis days).
Human immunodeficiency virus I infection (adults, treatment-naive or virologically suppressed on ISENTRESS 400 mg twice daily) 1200 mg (2 x 600 mg) once daily or 400 mg twice daily orally, with or without food.
Human immunodeficiency virus I infection (adults, treatment-experienced) 400 mg twice daily orally, with or without food.
Human immunodeficiency virus I infection (adults, coadministration with rifampin) 800 mg (2 x 400 mg) twice daily orally.
Human immunodeficiency virus I infection (pediatrics >= 40 kg, treatment-naive or virologically suppressed on ISENTRESS 400 mg twice daily) 1200 mg (2 x 600 mg) once daily, 400 mg twice daily, or 300 mg (3 x 100 mg) chewable tablets twice daily orally.
Human immunodeficiency virus I infection (pediatrics >= 25 kg) 400 mg film-coated tablet twice daily orally; weight-based chewable tablet dosing twice daily if unable to swallow tablet.
Human immunodeficiency virus I infection (pediatrics 3 kg to < 25 kg, >= 4 weeks of age) Weight-based dosing using chewable tablet or oral suspension twice daily orally (approximately 6 mg/kg/dose).
Human immunodeficiency virus I infection (neonates birth to 4 weeks, >= 2 kg) Weight-based oral suspension: once daily dosing (~1.5 mg/kg/dose) from birth to 1 week; twice daily dosing (~3 mg/kg/dose) from 1 to 4 weeks of age.
Contraindications
- Alfuzosin
- Carbamazepine
- Phenobarbital
- Phenytoin
- Rifampin
- Lurasidone
- Pimozide
- Dihydroergotamine
- Ergotamine
- Methylergonovine
- St. John's wort
- Lomitapide
- Lovastatin
- Simvastatin
- Sildenafil for pulmonary arterial hypertension
- Triazolam
- Orally administered midazolam
—
Adverse Reactions
Most common (>=5%) Nausea, diarrhea, headache, fatigue
Serious Severe acute exacerbations of hepatitis B, immune reconstitution syndrome, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis
Postmarketing Angioedema, urticaria, rash, acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome
Most common (>=2%) Headache, insomnia, nausea, dizziness, fatigue.
Serious Myopathy, rhabdomyolysis, hepatitis, hepatic failure, depression including suicidal ideation and behaviors, nephrolithiasis, renal failure, hypersensitivity.
Postmarketing Thrombocytopenia, diarrhea, hepatic failure, rhabdomyolysis, cerebellar ataxia, anxiety, paranoia.
Pharmacology
GENVOYA is a fixed-dose combination of elvitegravir (an integrase strand transfer inhibitor that prevents HIV-1 DNA integration into host genomic DNA), cobicistat (a CYP3A inhibitor that enhances elvitegravir exposure), emtricitabine (a nucleoside reverse transcriptase inhibitor that causes viral DNA chain termination), and tenofovir alafenamide (a prodrug converted to tenofovir diphosphate, which inhibits reverse transcriptase through DNA chain termination).
Raltegravir inhibits the catalytic activity of HIV-1 integrase, an HIV-1-encoded enzyme required for viral replication, preventing integration of unintegrated linear HIV-1 DNA into the host cell genome; it is eliminated primarily via UGT1A1-mediated glucuronidation and does not inhibit or induce cytochrome P450 enzymes.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Genvoya
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
Isentress
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Genvoya
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Isentress
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Genvoya
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Isentress
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
GenvoyaView full Genvoya profile
IsentressView full Isentress profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.